Amylin, Lilly diabetes drug falls short of Novo's (Reuters)
NEW YORK (Reuters) – A long-awaited experimental diabetes penalization from Eli Lilly & Co and Amylin Pharmaceuticals Inc unsuccessful to correct up to Novo Nordisk A/S's newborn Victoza take in a study.
Lilly, Amylin and relation Alkermes Inc released results of a head-to-head study on Thursday scrutiny their once-weekly Bydureon to Victoza, which is condemned daily. Bydureon is a longer-acting edition of Byetta, which is sold by Lilly and Amylin.
Shares of Nordic drugmaker Novo were up 4.5 percent after the announcement.
The U.S. Food and Drug Administration in Oct declined to okay Bydureon until more accumulation could be obtained on its possibleness gist on heart rates. Amylin said in Jan that the Bydureon application would be resubmitted to the bureau in the ordinal half of this year, and the agency's review would likely take up to six months.
(Reporting by adventurer Krauskopf, redaction by Gerald E. McCormick)
Source
0 comments:
Post a Comment